Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Immunoprecise Antibodies Ltd IPA

Technology Scientific & Technical Instruments
ImmunoPrecise Antibodies Ltd is a supplier of custom antibodies to the research industry and industrial community. The company has aggregated its operations into one reportable segment, Antibody Production, and Related Services. It operates in three principal geographical areas - the United States of America, Canada, Europe, and others. The majority of its revenue is derived from the United States of America.


NDAQ:IPA - Post by User

Immunoprecise Antibodies Ltd > Door is wide open for a efficacious therapeutic
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(22)
•••
Comment by wallpaper2on Jan 13, 2021 6:49am
136 Views
Post# 32283044

RE:Door is wide open for a efficacious therapeutic

RE:Door is wide open for a efficacious therapeutic Tell us something we don't already know.
The trials which were due to start in January and take 4 weeks to complete.
Have they begun and if so when?  Several companies have already completed these early
stage trials.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities